Meiji Seika Pharma

Privately held: no public share price · Japan

Assets

(4 total)
4Total Assets
2Approved
1Phase 3 / Filed
1Phase 1–2 / Early
9Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
Rho-associated kinase (ROCK, pan)Small molecule
Graft-versus-Host Disease
Chronic Graft-versus-Host Disease
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Phase 3
HDACSmall molecule
Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma
HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma
MorcamilastNo recent activity
Phase 2
PDE4Small molecule
Psoriasis

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
BelumosudilPhase 1/2Plasma Cell Myeloma Refractory
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
ChidamidePhase 3Colorectal Cancer
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
September 2028 (2)
BelumosudilPhase 2Chronic Graft Versus Host Disease
Est. primary completion 2028-09-25 · NCT07116031 · CT.gov ↗
What to watch
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2028-09-29 · NCT06143891 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
BelumosudilPhase 3Lung Transplant Rejection
Est. primary completion 2029-01-29 · NCT06082037 · CT.gov ↗
What to watch
September 2029 (1)
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2029-09-14 · NCT07771439 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
ChidamidePhase 3Lymphoma, T-Cell, Peripheral
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗

Financial reports

No financial reports recorded.